Article Text
Statistics from Altmetric.com
Welcome to this new feature forHeart Online (www.heartjnl.com) where we welcome your comments on topical issues in cardiology. Initially, views on the recent publication of the [National Institute for Clinical Excellence] NICE guidelines on IIb/IIIa inhibitors* are encouraged. These have produced many different reactions, and a certain amount of surprise.
If you want to comment on these guidelines, or other matters, please access this item on theHeart web site (www.heartjnl.com/cgi/content/full/84/6/586) and use the Rapid Response facility (click on eLetters: Submit a response to this article). Please limit your views to 750 words and 5 references, shorter if possible (sorry but we cannot accept images with this facility). Your views will be posted onHeart Online within a few days subject to editorial screening.
Supplementary materials
- THANKS TO REVIEWERS
The Editor and his team appreciate the help provided by all reviewers for Heart.
The following were the busiest reviewers for the journal in 2000:
A A J Adgey
A L Clark
P O Collinson
M R Cowie
H J G M Crijns
G Haywood
S T Irvine
R A Jones
J C Kaski
A D Kellion
G A Lanza
G Y H Lip
M Marzilli
T A McDonagh
J R McEwan
W J McKenna
K A McLeod
J J V McMurray
J M Morgan
F Murgatroyd
P Nihoyannopoulos
D Northridge
S R Redwood
R Schilling
A D Struthers
R Sutton
F Tomai
A Varnava
Footnotes
↵* A pdf version of “Guidance on the use of glycoprotein IIb/IIIa inhibitors in the treatment of acute coronary syndromes” (September 2000) is available from the NICE web site (www.nice.org.uk/nice-web/pdf/Nice+GLYCOPROTEIN+12+guidan.pdf)